Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each.
The company said that no stock purchase warrants are being issued in this at-the-market offering.
H.C. Wainwright & Co is acting as the exclusive placement agent for the offering.
Closing is expected to occur on or about September 20, 2024.
The company intends to use the funds raised for working capital and general corporate purposes.
Vivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea and snoring.